Antitumor vaccination with HER-2-derived recombinant antigens
Open Access
- 22 October 2002
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 102 (6), 660-664
- https://doi.org/10.1002/ijc.10785
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemiaGene Therapy, 2002
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer CellsJNCI Journal of the National Cancer Institute, 1995
- Correlation of Intrinsic Chemoresistance of Non-Small-Cell Lung Cancer Cell Lines With HER-2/neu Gene Expression but Not With ras Gene MutationsJNCI Journal of the National Cancer Institute, 1993
- Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells.The Journal of Experimental Medicine, 1993
- Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor CellsAdvances in Immunology, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase ActivityScience, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985